MEXACARE GmbH Revenue and Competitors

Heidelberg, Germany

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • MEXACARE GmbH's estimated annual revenue is currently $1.3M per year.(i)
  • MEXACARE GmbH's estimated revenue per employee is $251,000

Employee Data

  • MEXACARE GmbH has 5 Employees.(i)
  • MEXACARE GmbH grew their employee count by -29% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$19.6M7811%N/AN/A
#2
$142.3M567-3%N/AN/A
#3
$8.5M340%N/AN/A
#4
$58.7M23438%N/AN/A
#5
$15.1M6011%N/AN/A
#6
$73.5M29328%N/AN/A
#7
$28.4M11314%N/AN/A
#8
$22.3M8935%N/AN/A
#9
$96.4M384N/AN/AN/A
#10
$24.1M964%N/AN/A
Add Company

What Is MEXACARE GmbH?

MEXACARE GmbH is a supplier of point-of-care diagnostics with safe and easy to handle products: rapid tests for pregnancy, fertility and drugs of abuse as single test, multiple test panel or cassette test. All tests are designed for the day to day routine of medical professionals and show excellent user friendliness and reliability. Being produced to state-of-the-art standards, all rapidtests can be performed and validated without instruments. An offer which shows optimal value for money at highest quality. Test us.

keywords:N/A

N/A

Total Funding

5

Number of Employees

$1.3M

Revenue (est)

-29%

Employee Growth %

N/A

Valuation

N/A

Accelerator

MEXACARE GmbH News

2022-03-30 - MEXACARE besteht das große Audit ohne Hauptabweichungen und sichert sich somit die erneute europäische CE-Zertifizierung für die nächsten 3 Jahre

"MEXACARE GmbH unterliegt regelmäßigen, strengen Kontrollen seines gesamten Qualitätsmanagementsystems, welches nach DIN-ISO 13485:2016 zertifiziert ist. Im...

2022-02-22 - MEXACARE GmbH erhält als erster deutscher ISO-zertifizierter Hersteller die Zulassung für 2 COVID-19...

MEXACARE GmbH erhält als erster deutscher ISO-zertifizierter Hersteller die Zulassung für 2 COVID-19 Heim-Tests (Antikörper und Antigen).

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A50%N/A
#2
$0.7M5-55%N/A
#3
$0.9M10-9%N/A
#4
N/A100%N/A
#5
$2.4M2011%N/A